Dr. Karan Kumar completed his MD in Internal Medicine from the prestigious B J Medical College, Ahmedabad. Subsequently, he pursued his Doctorate in Medicine (DM) in Hepatology from the Institute of Liver and Biliary Sciences, New Delhi. Dr. Kumar possesses comprehensive training in managing a wide spectrum of complex liver diseases, with special interests in handling patients with acute liver failure, refractory ascites, liver cancer, and alcohol-related liver disease.
His expertise extends to optimizing liver transplantation patients, managing post-liver transplant complications, and providing long-term care for liver transplant recipients. Previously, he served as a consultant at BGS Gleneagles Global Hospital, Bangalore, for a duration of one year. Dr. Kumar has a notable academic record with over 25 publications in both national and international journals. He is a life member of prominent medical societies, including INASL, Liver Transplant Society of India, and the Indian Society of Gastroenterology.
-
-
-
-
Awarded Poster of Distinction at “The Liver Meeting” By American Association of Study of Liver Disease (AASLD) at San Francisco 2018
-
Best Oral Paper Presentation at “The International Liver congress” by European association of Study of Liver (EASL) at Vienna Austria-2019
-
Awarded Associate Fellow by National Academy of Medical Sciences-2022
-
Member of prominent medical societies, including INASL
-
Liver Transplant Society of India
-
The Indian Society of Gastroenterology.
-
Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. Hepatology Communications. 2023;7(5). doi:10.1097/hc9.0000000000000098
-
Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.1060073
-
Tinospora Cordifolia (Giloy)–Induced Liver Injury During the COVID-19 Pandemic—Multicenter Nationwide Study From India. Hepatology Communications. 2022;6(6):1289-1300. doi:10.1002/hep4.1904
-
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. Journal of Clinical and Experimental Hepatology. 2023;13(4):618-623. doi:10.1016/j.jceh.2023.02.003
-
Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Journal of Clinical and Experimental Hepatology. Published online June 2021. doi:10.1016/j.jceh.2021.06.019
-
EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS. Seminars in Liver Disease. Published online June 2022. doi:10.1055/a-1869-7607
-
Nonselective beta-blockers reduce mortality in patients with acute-on-chronic liver failure. Portal Hypertension & Cirrhosis. 2022;1(1):15-22. doi:10.1002/poh2.18
-
Role of microRNA in acute cellular rejection. Hepatology. 2017;65(4):1423-1424. doi:10.1002/hep.29063
-
mpact of COVID-19 on liver transplant recipients–A systematic review and meta-analysis. EClinicalMedicine. 2021;38:101025. doi:10.1016/j.eclinm.2021.10102
-
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.eClinicalMedicine. 2023;63:102179. doi:10.1016/j.eclinm.2023.102179
-
Primary Norfloxacin Prophylaxis for APASL Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. American Journal of Gastroenterology. 2022;Publish Ahead of Print. doi:10.14309/ajg.0000000000001611
-
Elevated Liver Chemistries in COVID-19—Is It Not a Concern. The American Journal of Gastroenterology. Published online 2020. doi:doi: 10.14309/ajg.0000000000000914
-
Letter: TIPSS and reversal of sarcopenia. Alimentary Pharmacology & Therapeutics. 2020;53(1):210-210. doi:10.1111/apt.16129
-
Letter to the Editor: Retreatment Decision for Hepatitis B Flare in HBeAg- Negative Chronic Hepatitis B. Hepatology. 2021;73(5):2081-2082. doi:10.1002/hep.31589
-
Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long- Term Nucleos(t)ide Analogue Therapy. Journal of Clinical and Experimental Hepatology. Published online August 2023. doi:10.1016/j.jceh.2023.08.008
-
Letter to the Editor: Sodium-Glucose Cotransporter-2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes. Hepatology. 2021;73(2):865-865. doi:10.1002/hep.31399
-
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH. Hepatology. 2021;74(6):3559-3560. doi:10.1002/hep.32094
-
Early prediction of decompensation in cirrhosis—Is it possible without aetiology and portal hypertension? Liver International. 2022;42(5):1206-1206. doi:10.1111/liv.15227
-
Prevention of paracentesis-induced circulatory dysfunction- a systematic review and network meta-analysis. GastroHep. 2020;2(3):138-138. doi:10.1002/ygh2.399
-
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary Pharmacology & Therapeutics. 2020;52(3):575-576. doi:10.1111/apt.15829
-
Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. Liver Transplantation. 2020;26(11):1539-1540. doi:10.1002/lt.25827
-
A rare case of systemic lupus erythromatosus with acalculous cholecystitis as its first presenting feature. International Journal of Advances in Medicine. Published online 2015:426-428. doi:10.18203/2349-3933.ijam20151024
-
A Multicentric Experience on Living Donor Liver Transplantation in Coronavirus Disease 2019 Hotspots in India. Liver Transplantation. Published online February 2021. doi:10.1002/lt.25957
-
Acute-on-Chronic Liver Failure. New England Journal of Medicine. 2020;383(9):892-894. doi:10.1056/nejmc2023198